© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
A panel of experts discuss renal cell carcinoma (RCC) using evidence-based data presented at the ASCO GU 2022 Annual Meeting this year.
March 16th 2022
Tian Zhang, MD, provides an overview of renal cell carcinoma (RCC).
Mehmet A. Bilen, MD, discusses the CLEAR trial that looked at lenvatinib with pembrolizumab as first-line therapy for RCC.
March 23rd 2022
Pedro C. Barata, MD, MSc, reviews the data from the KEYNOTE-426 trial, which focused on axitinib with pembrolizumab.
Moshe C. Ornstein, MD, MA, explains the results from the CheckMate 9ER trial that studied cabozantinib with nivolumab.
March 30th 2022
David Braun, MD, delves into data from the CheckMate 214 trial that focused on ipilimumab with nivolumab.
Dr Bilen discusses factors to consider when choosing a first-line therapy for advanced clear-cell RCC
April 6th 2022
7.Dr Ornstein explains how he selects between IO-TKI and IO-IO therapy in the first-line setting in advanced RCC.
Drs Barata and Ornstein describe how they treat certain subgroups of patients with advanced RCC, particularly those with brain or bone metastases.
April 13th 2022
Dr Braun explains how biomarkers help to stratify treatment decision-making for patients with RCC.
Dr Ornstein weighs in on interpreting quality of life data from important RCC trials to help with treatment decision-making.
April 20th 2022
The panel elaborates on novel agents and combination treatments that are currently being evaluated for the first-line setting in advanced RCC.
Mehmet A. Bilen, MD, explains how triplet regiments might impact treatment selection for first line and beyond.
April 27th 2022
Dr Zhang discusses recently approved adjuvant systemic therapy for patients with RCC who have a high risk of recurrence after nephrectomy.
David Braun, MD, touches on how the choice of adjuvant therapy can impact subsequent treatment selection in advanced RCC.
May 4th 2022
Dr Bilen reviews some ongoing trials looking into monotherapy and combination therapies in the adjuvant setting in RCC.
Pedro Barata, MD, MSc, provides a brief overview of ongoing trials in the neoadjuvant setting in patients with RCC.
May 11th 2022
Dr Ornstein describes how the choice of neoadjuvant therapy can impact subsequent treatment selection in advanced RCC.
Drs Zhang and Ornstein discuss regimens for advanced clear-cell RCC in the second-line setting and beyond, focusing on the METEOR, CABOSEQ,TIVO-3 CHeckMate 025, and AXIS trials.
May 18th 2022
Dr Barata comments on sequencing therapies in the second line and beyond in patients with advanced RCC.
Dr Bilen discusses the potential use of cabozantinib as a first-line therapy in patients who receive immunotherapy in the adjuvant setting.